BELLMAWR, New Jersey (WPVI) -- A young South Jersey boy has one wish for his birthday this year, and that is to help raise money for those living with a rare disease. Nine-year-old AJ Gonzales of ...

PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification ...

The Independent Data Monitoring Committee recommended transitioning patients in the placebo arm to garetosmab as soon as possible. Topline data were announced from a phase 3 trial evaluating ...

Ipsen’s fidrisertib has failed to show meaningful benefit above placebo in a Phase II trial in patients with fibrodysplasia ossificans progressiva (FOP). In the FALKON study (NCT05039515), fidrisertib ...